World Health Organization site
Skip Navigation Links

Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ISRCTN
Last refreshed on: 14 July 2014
Main ID:  ISRCTN86722376
Date of registration: 19/12/2005
Primary sponsor: Trimbos-instituut Netherlands Institute of Mental Health and Addiction
Public title: Randomized controlled trial of psychiatric consultation embedded in continuing education to company physicians for employees with sick leave absence through psychiatric disorders BACO Trial
Scientific title:
Date of first enrolment: Oct 3 2005
Target sample size: 400
Recruitment status: Completed/Not recruiting
Study type:  Interventional
Study design:  Randomised controlled trial  
Countries of recruitment
Key inclusion & exclusion criteria
Inclusion criteria: Employees with absence from work for a period of at least 6 weeks and no plan for resumption of work within 12 weeks, and a positive screen on either the PHQ or the Whiteley Index.

Exclusion criteria: Insufficient command of Dutch language, negative outcome of PHQ screen, dementia, psychotic symptoms or suicide risk, or the expectation of the company physician of a work related conflict.

Age minimum:
Age maximum:
Health Condition(s) or Problem(s) studied
Psychiatric, mental disorders/illness, depressive disorders, anxiety disorders
Company physicians are randomised over 2 conditions:
1. The intervention group
2. Care-as-usual group
All company physicians in both conditions receive continuing education and follow a training programme targeted at diagnosis and treatment of depressive disorder and anxiety disorder.
In the intervention group patients of company physicians receive psychiatric consultation as well, resulting in an individually tailored diagnosis and treatment advice.
These psychiatric consultations are embedded in the continuing education to company physicians.
Primary Outcome(s)
Reduction of symptoms as measured with the PHQ and quality of life as measured with the SF-20.
Secondary Outcome(s)
Number of complaints, general functioning, fatigue, duration of sick leave.
Secondary ID(s)
Source(s) of Monetary Support
ArboUnie, ArboNed, STECR Alladin Program
Secondary Sponsor(s)
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.1 - Version history